ssa retatrutide Promises Big Weight Loss, but Safety Remains a Question Retatrutide Half-Life Explained | How

Ongoing trials by Novo Nordisk aim to explore the link between semaglutide use and diabetic retinopathy, with results expected by 2027

Durvi Patel Dr

The therapeutic class is experiencing unprecedented demand as prescriber awareness of pleiotropic benefits, including kidney disease event reduction and major adverse cardiovascular event reduction, reshapes treatment algorithms

H.McguireJ

Also the confusion between a true micro dose (not for weight) and a low dose and why people feel more comfortable with calling it microdosing belies more about weight health bias that we need to unpack - the shame about using this tool is driving a lot of suboptimal outcomes thx for shining a light Joanna Strober Agreed

It is also licensed for weight management in adolescents aged 12 years and above with obesity